Health and Healthcare

AbbVie : ABBV

All AbbVie Articles

606 Articles

Chris Lange | Feb 18, 2015 at 8:50 AM EST

Neurocrine Biosciences Announces New Offering

Neurocrine Biosciences has announced that it will have another public offering of its common stock to raise roughly $225 million.

Jon C. Ogg | Feb 9, 2015 at 8:45 AM EST

Top Analyst Upgrades and Downgrades: AbbVie, Alcoa, Apple, Deckers, Dish, Pfizer, Petrobras and More

Monday's top analyst upgrades, downgrades and initiations include AbbVie, Alcoa, Apple, Deckers Outdoor, Dish Network, Pfizer and Petrobras.

Lee Jackson | Feb 5, 2015 at 10:00 AM EST

Large Cap Pharmaceutical Stocks to Buy Despite Negative Pricing Headlines

If there is one thing that the pharmaceutical industry tries to shy away from it is the controversy over the…

Chris Lange | Feb 3, 2015 at 12:20 PM EST

What to Expect From Gilead Earnings

Tuesday after the U.S. markets close, Gilead Sciences will report its fourth-quarter financial results.

Chris Lange | Jan 30, 2015 at 8:55 AM EST

Are Humira Sales Enough to Lift AbbVie?

AbbVie reported better-than-expected fourth-quarter financial results Friday before the markets open.

Chris Lange | Jan 9, 2015 at 11:00 AM EST

Gilead Continues to Recover from Express Scripts Loss

Gilead Sciences was picked up by Anthem to provide its hepatitis C drug as the primary option for patients.

Chris Lange | Dec 29, 2014 at 10:45 AM EST

Is Gilead Already Coming Back Into Favor?

Is it possible that Gilead Sciences is already coming back into favor after just a week of being in the…

Chris Lange | Dec 23, 2014 at 12:15 PM EST

Analysts Predict Big Value Trap for Gilead Investors

Analysts are beginning to make their calls for what the future will hold for Gilead Sciences, AbbVie and Express Scripts.

Chris Lange | Dec 22, 2014 at 1:20 PM EST

What the AbbVie and Express Script Deal Means for Gilead

AbbVie and Express Scripts have entered into an exclusive agreement under which Express Scripts will distribute AbbVie's hepatitis treatment.

Jon C. Ogg | Dec 11, 2014 at 8:20 AM EST

Top Analyst Upgrades and Downgrades: ARIAD, FedEx, Genpact, Suncor, Travelers, UPS and More

Thursday's top analyst upgrades and downgrades from 24/7 Wall St. include ARIAD Pharmaceuticals, FedEx, Genpact, Suncor Energy, Travelers and UPS.

Jon C. Ogg | Nov 14, 2014 at 8:45 AM EST

Top Analyst Upgrades and Downgrades: Harley-Davidson, Lululemon, Nike, SunPower, Walmart and More

Friday's top analyst upgrades, downgrades and initiations include Harley-Davidson, Lululemon, Nike, SunPower and Walmart.

Lee Jackson | Nov 13, 2014 at 9:15 AM EST

4 Top Pharmaceutical Companies Helping Combat Hepatitis C Near Epidemic

A new research report from the analysts at UBS focuses on four companies that stand to benefit from rising demand…

Paul Ausick | Oct 27, 2014 at 10:45 AM EDT

The 7 Most Heavily Shorted NYSE Stocks

Only one of the seven stocks traded on the New York Stock Exchange with the largest number of shares held…

Lee Jackson | Oct 17, 2014 at 8:35 AM EDT

UBS’s Big List of Quality Stocks to Buy Now

UBS polled all of its analysts, who came up with 26 stocks by now. Here are the ones that offer…

Trey Thoelcke | Oct 10, 2014 at 7:20 AM EDT

Sprint Drops From the 5 Most Shorted NYSE Stocks

The most shorted stocks on the New York Stock Exchange at the September 30 settlement dates saw rising short interest…

1 … 36 37 38 39 40 41

AbbVie : ABBV

All AbbVie Articles

Neurocrine Biosciences Announces New Offering

Top Analyst Upgrades and Downgrades: AbbVie, Alcoa, Apple, Deckers, Dish, Pfizer, Petrobras and More

Large Cap Pharmaceutical Stocks to Buy Despite Negative Pricing Headlines

What to Expect From Gilead Earnings

Are Humira Sales Enough to Lift AbbVie?

Gilead Continues to Recover from Express Scripts Loss

Is Gilead Already Coming Back Into Favor?

Analysts Predict Big Value Trap for Gilead Investors

What the AbbVie and Express Script Deal Means for Gilead

Top Analyst Upgrades and Downgrades: ARIAD, FedEx, Genpact, Suncor, Travelers, UPS and More

Top Analyst Upgrades and Downgrades: Harley-Davidson, Lululemon, Nike, SunPower, Walmart and More

4 Top Pharmaceutical Companies Helping Combat Hepatitis C Near Epidemic

The 7 Most Heavily Shorted NYSE Stocks

UBS’s Big List of Quality Stocks to Buy Now

Sprint Drops From the 5 Most Shorted NYSE Stocks

AI XRP Price Prediction: Claude Fable 5 Predicts the XRP Price for End of 2026

The Monthly Income Trap: How JEPQ Investors Gave Up $18,000 Per $10,000 Invested Since Inception

‘The Borrower Is Slave to the Lender’: Dave Ramsey Warns a 22-Year-Old Against Letting a Rich Friend Pay Off His $70,000 Debt

'The Borrower Is Slave to the Lender': Dave Ramsey Warns a 22-Year-Old Against Letting a Rich Friend Pay Off His $70,000 Debt

$1 Million in Retirement Savings Spends Like $40,000 a Year. Here's Why That's Not Enough.

AI XRP Price Prediction: Claude Fable 5 Predicts the XRP Price for End of 2026

The Monthly Income Trap: How JEPQ Investors Gave Up $18,000 Per $10,000 Invested Since Inception

AbbVie : ABBV

All AbbVie Articles

Neurocrine Biosciences Announces New Offering

Top Analyst Upgrades and Downgrades: AbbVie, Alcoa, Apple, Deckers, Dish, Pfizer, Petrobras and More

Large Cap Pharmaceutical Stocks to Buy Despite Negative Pricing Headlines

What to Expect From Gilead Earnings

Are Humira Sales Enough to Lift AbbVie?

Gilead Continues to Recover from Express Scripts Loss

Is Gilead Already Coming Back Into Favor?

Analysts Predict Big Value Trap for Gilead Investors

What the AbbVie and Express Script Deal Means for Gilead

Top Analyst Upgrades and Downgrades: ARIAD, FedEx, Genpact, Suncor, Travelers, UPS and More

Top Analyst Upgrades and Downgrades: Harley-Davidson, Lululemon, Nike, SunPower, Walmart and More

4 Top Pharmaceutical Companies Helping Combat Hepatitis C Near Epidemic

The 7 Most Heavily Shorted NYSE Stocks

UBS’s Big List of Quality Stocks to Buy Now

Sprint Drops From the 5 Most Shorted NYSE Stocks

AI XRP Price Prediction: Claude Fable 5 Predicts the XRP Price for End of 2026

The Monthly Income Trap: How JEPQ Investors Gave Up $18,000 Per $10,000 Invested Since Inception

‘The Borrower Is Slave to the Lender’: Dave Ramsey Warns a 22-Year-Old Against Letting a Rich Friend Pay Off His $70,000 Debt

Featured Reads

'The Borrower Is Slave to the Lender': Dave Ramsey Warns a 22-Year-Old Against Letting a Rich Friend Pay Off His $70,000 Debt

$1 Million in Retirement Savings Spends Like $40,000 a Year. Here's Why That's Not Enough.